Deal-starved banks lined up to make concessions to get a slice of Europe’s biggest buyout debt deal last year. They also put ...

The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the earliest, completing its transition into a pure-play drug and vaccine ...

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

Sanofi SNY reported fourth-quarter 2024 adjusted earnings of 70 cents per American depositary share, which missed the Zacks Consensus Estimate of 71 cents per share. Earnings of €1.31 per share ...

(RTTNews) - Sanofi's Consumer Healthcare division, Opella, announced that the U.S. Food and Drug Administration has lifted a clinical hold on its planned actual use trial (AUT). The trial is aimed ...

While Opella has long operated as a standalone unit within Sanofi, boasting more than 11,000 employees across 100 countries, Sanofi in October proposed a plan to sell a 50% controlling stake to U ...

Intention to sell a controlling stake in Opella consumer health at an attractive ... performing stocks on TipRanks >> Read More on SNY: Sanofi NewsMORE Related Stocks Indices Commodities ...

Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT ...

The sale of Sanofi's controlling stake in health business Opella is expected to close in the second quarter at the earliest, completing its transition into a pure-play drug and vaccine manufacturer.

Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to ...